Topic
17 stories from Planck Standard. Latest: September 20, 2026.
The JCI Insight study maps 'loss of Y' from healthy tissue through precancerous cells to full malignancy for the first time and finds it strongest around colon, rectal, esophageal, pancreatic and lung cancers. Its senior author says it may be 'one of the earliest signposts of cancer forming.'
The 'lemon frost' leopard gecko develops aggressive, spreading tumors in 80% of individuals — and University of Nottingham scientists found its cancers share key genetic faults with our own.
In preclinical experiments, the widely used medication telmisartan sharply boosted the tumor-killing power of the targeted drug olaparib and rallied the immune system to join the attack.
WashU scientists expected their mRNA vaccine to flop in mice missing the dendritic cells thought to be essential. Instead a related cell stepped in — overturning a core assumption and pointing toward sturdier shots.
Japanese researchers screening microbes from tree frogs, newts and lizards found one strain that erased colorectal tumors entirely — outperforming standard chemotherapy and immunotherapy in the lab.
UCLA researchers report that the popular muscle-building compound energizes dendritic cells — the immune system's scouts — potentially making cancer immunotherapy work for far more patients.
University of Pittsburgh researchers identified a long-hidden genetic partner, TPP1, that teams up with a known mutation to give the deadly skin cancer its runaway lifespan.
University of Washington scientists found that fibrolamellar carcinoma hides from immunotherapy by sequestering T cells in fibrous tissue — and that the FDA-approved drug AMD3100 lets them back in to kill the tumor.
A Hokkaido University team found that whether a cell with a doubled genome lives or dies depends on how the division error occurred, pointing to a possible vulnerability in recurring tumors.
Gabbard becomes Trump's fourth cabinet secretary to leave in three months as she steps away to support her husband's cancer treatment.
Lead author Rosalie Sears shows phosphorylated MYC physically migrates to damaged DNA in tumor cells, opening a new combination strategy with first-in-class inhibitor OMO-103.
Pre-surgical pembrolizumab erased detectable disease in more than half of UCL-led trial patients, with no relapses after 33 months.
High court will hear arguments in landmark case that could end litigation claiming Bayer's herbicide causes cancer.
The pharmaceutical giant bets on revolutionary in vivo CAR-T technology that reprograms patients' immune cells inside the body. The deal represents Lilly's largest acquisition in years.
University of Geneva researchers found cancer spread follows a predictable molecular program, and their MangroveGS tool can read it from standard tumor RNA sequencing.
MangroveGS, developed at the University of Geneva, analyzes hundreds of gene expression signatures to predict metastatic risk in colon, stomach, lung, and breast cancers with roughly 80 percent accuracy, revealing that cancer spread follows conserved biological programs rather than random mutations.
A team at Shandong University modified the probiotic bacterium E. coli Nissle 1917 to seek out breast cancer tumors in mice, colonize them, and produce the FDA-approved drug Romidepsin directly at the tumor site — opening a potential new path for targeted chemotherapy with fewer systemic side effects.